Vasomedical

Vasomedical is engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP® ) therapy systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system diseases that is cleared by the FDA and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance, and a staff training and maintenance programs designed to provide optimal patient outcomes. The Company also provides other non-invasive medical equipment including a full range of Biox™ ECG Holter monitors recorders and ambulatory blood pressure monitors.
Type
Public
HQ
Plainview, US
Founded
1994
Employees
218 (est)
Vasomedical was founded in 1994 and is headquartered in Plainview, US

Vasomedical Locations

Plainview, US
New York, US

Vasomedical Metrics

Vasomedical Summary

Market capitalization

$21.7 M

Closing share price

$0.134
Vasomedical's current market capitalization is $21.7 M.

Vasomedical Financials

Vasomedical's revenue is $57.1 M in FY, 2015 which is 63.31% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$32.9 M$35 M$57.1 M

Gross profit

$22.5 M$25.2 M$35.4 M

Operating income

$-1.29 M$1.06 M$3.94 M

Operating expense total

$23.8 M$24.1 M$31.4 M

Net Income

$-1.15 M$1.13 M$3.82 M

Operating cash flow

$-3.51 M$1.17 M$-6.97 M

    Vasomedical Market Value History

    Vasomedical Online Presence

    Vasomedical Company Life

    You may also be interested in